The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, DC on April 22, 2025. Nathan Posner | Anadolu | Getty Images A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the…
Investors are concerned about the fates of multiple experimental drugs for hard-to-treat diseases following a string of recent rejections from the U.S. Food and Drug Administration. The FDA in the past year has denied or discouraged the applications of at least eight drugs, according to RTW Investments, including a gene therapy for Huntington’s disease from…
Thomas Fuller | SOPA Images | Lightrocket | Getty Images UniQure needs to run another study to prove that its gene therapy “actually helps people with Huntington’s disease,” a senior U.S. Food and Drug Administration official said on a call with reporters Thursday. The official, who requested anonymity before discussing sensitive information, confirmed the agency…
We are buying 90 shares of Cardinal Health at roughly $217. Following the trade, Jim Cramer’s Charitable Trust will own 350 shares of Cardinal, increasing its weighing to about 2% from 1.46%. We may have started a new position in Cardinal Health too early this week, but the silver lining is that the stock’s drop…
As NFL quarterback Boomer Esiason was about to step onto the practice field for the New York Jets in 1993, shortly after being traded to the team, he was quickly pulled off to take an urgent phone call from his wife, Cheryl. Their two-year-old son, Gunnar, had been rushed to Cincinnati Children’s Hospital. Shortly thereafter,…
Jim Cramer on Tuesday morning explained why the Investing Club is trying to strike a delicate balance with its moves during the stock market fallout from the Iran war. “Those who flee in moments like this can never get back in,” Jim stressed during the Morning Meeting, as Wall Street sold off sharply on the…
Jim Cramer’s advice for investors navigating fallout from the U.S.-Israeli attack on Iran: Be selective. With stocks initially selling off (but way off their lows in late morning trading; stay tuned) and oil spiking on supply-disruption fears, Jim sees moves to make on the first Wall Street trading day since the conflict began. But, at…
On Friday, the CNBC Investing Club held its February Monthly Meeting, where Jim Cramer and Director of Portfolio Analysis ran through each stock in the portfolio. Jim put a special focus on the Club stocks within the artificial intelligence trade. He’s dubbed them the “Fourth Industrial Revolution stocks,” borrowing the term from Nvidia CEO Jensen…
We added a new Bullpen name during Friday’s Monthly Meeting, and it has minimal economic sensitivity and faces little to no artificial intelligence disruption risk. It’s Cardinal Health , a company that is the backbone of the U.S. health-care industry. The Bullpen is our watchlist of stocks that we want to consider buying for Jim…
A sign of Swiss pharmaceutical giant Novartis is seen on the top of a building at Novartis Campus in Basel on Sept. 9, 2025. Fabrice Coffrini | AFP | Getty Images Novartis, one of the world’s largest pharmaceutical companies, and Genentech, a major biotech firm, say they’ve uncovered a “dangerous scheme” to import their allergy…
